SG91296A1 - A novel crystalline form of 6-hydroxy-3-[4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo [b] thiophene hydrochloride - Google Patents

A novel crystalline form of 6-hydroxy-3-[4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo [b] thiophene hydrochloride

Info

Publication number
SG91296A1
SG91296A1 SG200004288A SG200004288A SG91296A1 SG 91296 A1 SG91296 A1 SG 91296A1 SG 200004288 A SG200004288 A SG 200004288A SG 200004288 A SG200004288 A SG 200004288A SG 91296 A1 SG91296 A1 SG 91296A1
Authority
SG
Singapore
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
ethoxy
Prior art date
Application number
SG200004288A
Other languages
English (en)
Inventor
Kay Bush Julie
Charles Conrad Preston
Gerard Flom Merlyn
Douglas Luke Wayne
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG91296A1 publication Critical patent/SG91296A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200004288A 1999-07-29 2000-07-28 A novel crystalline form of 6-hydroxy-3-[4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo [b] thiophene hydrochloride SG91296A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (1)

Publication Number Publication Date
SG91296A1 true SG91296A1 (en) 2002-09-17

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200004288A SG91296A1 (en) 1999-07-29 2000-07-28 A novel crystalline form of 6-hydroxy-3-[4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo [b] thiophene hydrochloride

Country Status (45)

Country Link
EP (1) EP1204656A2 (fr)
JP (1) JP2001064277A (fr)
KR (1) KR100697177B1 (fr)
CN (1) CN1138770C (fr)
AR (1) AR031073A1 (fr)
AT (1) AT502318A1 (fr)
AU (1) AU6335600A (fr)
BE (1) BE1013411A3 (fr)
BR (1) BR0003209A (fr)
CA (1) CA2314682A1 (fr)
CO (1) CO5180570A1 (fr)
CZ (1) CZ299311B6 (fr)
DE (1) DE10036854A1 (fr)
DK (1) DK200001151A (fr)
DZ (1) DZ3060A1 (fr)
FI (1) FI20001722A (fr)
FR (1) FR2796944B1 (fr)
GB (1) GB2352717A (fr)
GR (1) GR1004084B (fr)
HK (1) HK1035370A1 (fr)
HR (1) HRP20000503B1 (fr)
HU (1) HUP0003001A2 (fr)
ID (1) ID27078A (fr)
IL (1) IL137553A (fr)
IT (1) IT1318660B1 (fr)
LT (1) LT4790B (fr)
LU (1) LU90617B1 (fr)
LV (1) LV12623B (fr)
MD (1) MD2336G2 (fr)
MX (1) MXPA00007461A (fr)
MY (1) MY128764A (fr)
NL (1) NL1015821C2 (fr)
NO (1) NO20003879L (fr)
PE (1) PE20010385A1 (fr)
PL (1) PL341749A1 (fr)
PT (1) PT102502A (fr)
RO (1) RO121851B1 (fr)
SE (1) SE0002792L (fr)
SG (1) SG91296A1 (fr)
SI (1) SI20426A (fr)
SV (1) SV2002000132A (fr)
TR (1) TR200002206A2 (fr)
TW (1) TWI276437B (fr)
UA (1) UA72885C2 (fr)
WO (1) WO2001009116A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208384T3 (es) * 1999-07-29 2004-06-16 Eli Lilly And Company Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
CN1283250C (zh) * 2000-05-08 2006-11-08 伊莱利利公司 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩及其盐的稳定制剂
EP1757291A3 (fr) * 2000-05-08 2009-07-15 Eli Lilly & Company Formulations stabilisées de 6-hydroxy-3-(4- 2-(pipéridin-1-yl)éthoxyphénoxy)-2-(4-methoxyphényl) benzo(b)thiophène et sels de ces composés
EP1157996A1 (fr) * 2000-05-23 2001-11-28 JENAPHARM GmbH Nouveaux formes solides du mesoprogestin 11beta-(4E-(hxdroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
CN1268624C (zh) * 2000-10-20 2006-08-09 伊莱利利公司 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
WO2002042289A2 (fr) 2000-11-27 2002-05-30 Eli Lilly And Company Procede de preparation de 3-aryl-benzo[b]thiophenes
CA2393720C (fr) * 2002-07-12 2010-09-14 Eli Lilly And Company Monochlorhydrate de 3-(1-methyl-1h-indol-3-yl)-4-[[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione cristallin
AU2005275185B2 (en) * 2004-07-22 2011-06-23 Eli Lilly And Company A crystalline variable hydrate of (S)-6-(4-(2-((3-(9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723474A (en) * 1995-02-28 1998-03-03 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729956B1 (fr) * 1995-02-28 2001-10-31 Eli Lilly And Company Composés du benzothiophène, intermédiaires, compositions et méthodes
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723474A (en) * 1995-02-28 1998-03-03 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods

Also Published As

Publication number Publication date
CN1138770C (zh) 2004-02-18
AR031073A1 (es) 2003-09-10
DK200001151A (da) 2001-01-30
LU90617B1 (fr) 2001-06-15
KR100697177B1 (ko) 2007-03-21
GR20000100265A (el) 2001-03-30
GR1004084B (el) 2002-12-11
HRP20000503A2 (en) 2001-06-30
LT4790B (lt) 2001-05-25
HK1035370A1 (en) 2001-11-23
SI20426A (sl) 2001-06-30
IL137553A0 (en) 2001-07-24
CZ299311B6 (cs) 2008-06-18
IE20000605A1 (en) 2001-04-04
SE0002792L (sv) 2001-01-30
RO121851B1 (ro) 2008-06-30
NL1015821A1 (nl) 2001-01-30
GB0018641D0 (en) 2000-09-13
GB2352717A (en) 2001-02-07
FR2796944A1 (fr) 2001-02-02
UA72885C2 (uk) 2005-05-16
DZ3060A1 (fr) 2004-05-22
MD2336F2 (en) 2003-12-31
TR200002206A2 (tr) 2001-03-21
HU0003001D0 (en) 2000-10-28
FR2796944B1 (fr) 2003-01-31
AT502318A1 (de) 2007-02-15
JP2001064277A (ja) 2001-03-13
PT102502A (pt) 2001-01-31
MD2336G2 (ro) 2004-06-30
SV2002000132A (es) 2002-06-07
NO20003879D0 (no) 2000-07-28
MXPA00007461A (es) 2004-07-16
NO20003879L (no) 2001-01-30
TWI276437B (en) 2007-03-21
FI20001722A0 (fi) 2000-07-28
LV12623B (en) 2001-07-20
BE1013411A3 (fr) 2001-12-04
PL341749A1 (en) 2001-02-12
DE10036854A1 (de) 2001-03-01
PE20010385A1 (es) 2001-04-06
NL1015821C2 (nl) 2002-01-03
WO2001009116A2 (fr) 2001-02-08
HRP20000503B1 (en) 2008-04-30
ITMI20001759A1 (it) 2002-01-28
WO2001009116A3 (fr) 2001-05-17
ID27078A (id) 2001-02-22
AU6335600A (en) 2001-02-19
SE0002792D0 (sv) 2000-07-28
MY128764A (en) 2007-02-28
CO5180570A1 (es) 2002-07-30
HUP0003001A2 (hu) 2002-04-29
CZ20002716A3 (en) 2001-05-16
KR20010049916A (ko) 2001-06-15
LV12623A (en) 2001-03-20
MD20000162A (en) 2001-04-30
CA2314682A1 (fr) 2001-01-29
IT1318660B1 (it) 2003-08-27
LT2000076A (lt) 2001-02-26
IL137553A (en) 2005-09-25
FI20001722A (fi) 2001-01-30
CN1288007A (zh) 2001-03-21
EP1204656A2 (fr) 2002-05-15
ITMI20001759A0 (it) 2000-07-28
BR0003209A (pt) 2001-03-20

Similar Documents

Publication Publication Date Title
IL137552A0 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
SG91296A1 (en) A novel crystalline form of 6-hydroxy-3-[4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo [b] thiophene hydrochloride
IL155487A0 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
CY2344B1 (en) A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
ZA200003838B (en) A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
IL152699A0 (en) STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO [b] THIOPHENE AND SALTS THEREOF
TJ399B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ- phenoxy) -2-(4-methoxyphenyl) benzo ÄBÜ thiophene hydrochloride.
TJ398B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.